Cardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. Its offerings include Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment blood test targeting CHD events such as heart attacks; PrecisionCHD, an integrated epigenetic-genetic blood test for detecting coronary heart disease; and Actionable Clinical Intelligence, a platform providing epigenetic and genetic insights to clinicians to help improve chronic care management. The company also provides CardioInnovate360, a research-use-only solution for discovering, developing, and validating novel biopharmaceuticals for cardiovascular disease assessment and management, and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers, provider organizations such as concierge practices, longevity clinics, and risk-bearing provider organizations, as well as employer organizations. Founded in 2017, Cardio Diagnostics Holdings, Inc. is headquartered in Chicago, Illinois.